Abstract: An experiment of processing a device is performed to acquire type 1 information and type 2 information indicating processing conditions, and type 3 information and type 4 information indicating results of the processing, derive a first relation between the type 1 information, the type 2 information, and the type 3 information, and a second relation between the type 1 information, the type 2 information, and the type 4 information, and generate and output a model that estimates the type 4 information indicating a result of the processing by using the first relation and the second relation with the type 2 information and the type 3 information that are measured during the processing as inputs.

Abstract: Systems and methods for use in wastewater treatment plants that use aerobic digestion are provided. The systems and methods precipitate phosphates from the supernatant of an aerobic digest to produce a brushite-containing sludge, at least a portion of which is recirculated back into the aerobic digest. The methods reduce phosphate in the reject water produced by dewatering an aerobic digestate, while maintaining the pH of the aerobically digested sludge in a suitable range for polymer flocculants commonly used in sludge dewatering.

Abstract: Experimental device machining is performed according to plan information including first type information indicating a first type condition of the experimental device machining and second type information indicating a second type condition of the experimental device machining. Third type information indicating a third type result and fourth type information indicating a fourth type result are acquired. Extended plan information is acquired in which a uniformity of extended second type information and extended third type information is equal to or greater than a threshold value. Extended third type information indicating a third type result and extended fourth type information indicating a fourth type result are acquired by performing the experimental device machining according to the extended plan information. An extended first relationship is derived that is a relationship between extended first type information, the extended second type information, and the extended third type information.

Abstract: A processor performs an experiment of machining a device to acquire first-type and second-type information each indicating conditions of the experiment of machining and third-type and fourth-type information each indicating a result of the experiment of machining (S401). The processor derives a first expression and a second expression, where the first expression receives first-type and second-type information as inputs and outputs third-type information as more than one solution, and the second expression receives first-type and second-type information as inputs and outputs fourth-type information. The processor derives more than one third expression from the first expression, where the more than one third expression each receives second-type and third-type information as inputs and outputs first-type information (S402).

Abstract: An experiment of processing a device is performed to acquire type 1 information and type 2 information indicating processing conditions, and type 3 information and type 4 information indicating results of the processing, derive a first relation between the type 1 information, the type 2 information, and the type 3 information, and a second relation between the type 1 information, the type 2 information, and the type 4 information, and generate and output a model that estimates the type 4 information indicating a result of the processing by using the first relation and the second relation with the type 2 information and the type 3 information that are measured during the processing as inputs.

Abstract: A thermal fluid analysis method includes: calculating volumes of air blown out of blowout holes using a physical model; setting at least one virtual blowout hole corresponding to a mesh of a two-dimensional model of a space to be cooled; allotting one or more of the blowout holes to each of the at least one virtual blowout hole; calculating an equivalent volume of air blown out of the at least one virtual blowout hole based on the volumes of the air blown out of the one or more blowout holes; and setting, as an analysis parameter of the two-dimensional model, a physical amount related to the equivalent volume.

Abstract: The present invention relates to an antibody which has a therapeutic effect on cancer, an autoimmune disease, or an inflammatory disease. That is, the present invention relates to an antibody which exhibits a cytotoxic activity against death domain-containing receptor-expressing cells through apoptosis. [Object] An object of the invention is to provide a pharmaceutical having a therapeutic effect on cancer. [Means for Resolution] A novel anti-DR5 antibody capable of inducing apoptosis in cells has more potent cytotoxic activity than currently available anti-DR5 antibodies.

Abstract: The present invention relates to an antibody which has a therapeutic effect on cancer, an autoimmune disease, or an inflammatory disease. That is, the present invention relates to an antibody which exhibits a cytotoxic activity against death domain-containing receptor-expressing cells through apoptosis. [Object] An object of the invention is to provide a pharmaceutical having a therapeutic effect on cancer. [Means for Resolution] A novel anti-DR5 antibody capable of inducing apoptosis in cells has more potent cytotoxic activity than currently available anti-DR5 antibodies.

Abstract: A temperature sensor includes a sheath member having an insulative holding member which contains an oxygen supplying substance and is formed in such a manner that the oxygen supplying substance is exposed when viewed from an opening on the distal end side of a sheath tube. Since the insulative holding member releases oxygen from the distal end side of the sheath member, a decrease in oxygen concentration around a thermistor element can be suppressed. Thus, it is possible to suppress a change in the characteristics of the thermistor element due to reduction action, and to suppress decrease in temperature detection accuracy. Since the oxygen supplying substance is contained in the insulative holding member, compared with a configuration where a pellet is disposed on the distal end side of the thermistor element, delay in heat conduction is less likely to occur, and a decrease in temperature detection response can be suppressed.

Abstract: The present invention relates to an antibody which has a therapeutic effect on cancer, an autoimmune disease, or an inflammatory disease. That is, the present invention relates to an antibody which exhibits a cytotoxic activity against death domain-containing receptor-expressing cells through apoptosis. [Object] An object of the invention is to provide a pharmaceutical having a therapeutic effect on cancer. [Means for Resolution] A novel anti-DR5 antibody capable of inducing apoptosis in cells has more potent cytotoxic activity than currently available anti-DR5 antibodies.

Abstract: The present invention relates to an antibody which has a therapeutic effect on cancer, an autoimmune disease, or an inflammatory disease. That is, the present invention relates to an antibody which exhibits a cytotoxic activity against death domain-containing receptor-expressing cells through apoptosis. [Object] An object of the invention is to provide a pharmaceutical having a therapeutic effect on cancer. [Means for Resolution] A novel anti-DR5 antibody capable of inducing apoptosis in cells has more potent cytotoxic activity than currently available anti-DR5 antibodies.

Abstract: The present invention relates to an immunoliposome preparation or a hydrophobic molecule-modified antibody having a therapeutic effect on cancer, autoimmune disease, or inflammatory disease. Specifically, the present invention relates to an immunoliposome or a hydrophobic molecule-modified antibody comprising, as a constituent, an antibody capable of inducing the apoptosis of cells expressing a death domain-containing receptor.

Abstract: Ligand Drug Conjugates are provided having a DR5 binding moiety attached via linking groups and/or spacers to a therapeutic agent and are effective in treatment of various cancers.

Abstract: The present invention provides a cell activation agent, a collagen production accelerator, a whitening agent, an antioxidant, an anti-inflammatory agent, an aromatase activity accelerator, a protease activity accelerator, a skin external preparation, and food, which all contain an extract of Hibiscus makinoi.

Abstract: The present invention relates to an immunoliposome preparation having a therapeutic effect on cancer, autoimmune disease, or inflammatory disease. Specifically, the present invention relates to an immunoliposome comprising, as a constituent, an antibody capable of inducing the apoptosis of cells expressing a death domain-containing receptor.

Abstract: The present invention provides a cell activation agent, a collagen production accelerator, a whitening agent, an antioxidant, an anti-inflammatory agent, an aromatase activity accelerator, a protease activity accelerator, a skin external preparation, and food, which all contain an extract of Hibiscus makinoi.

Abstract: Anti-Fas antibodies which are cross-reactive with mouse and human Fas and are useful in the treatment of conditions attributable to abnormalities in the Fas/Fas ligand system.

Abstract: A pharmaceutical composition containing an anti-human Fas antibody having apoptosis inducing activity and a compound having a folate antagonist activity or a dihydrofolate reductase inhibiting activity, as active ingredients for the prophylaxis and/or treatment of an autoimmune disease or rheumatoid arthritis. According to the present invention, the amount of the anti-Fas antibody to be used can be reduced and thereby the possibility that a patient may become tolerant to anti-Fas antibody as a result of the production of antibodies against the anti-Fas antibody in the patient's body or the like can be decreased, and thus is provided a pharmaceutical composition which can be used for a long time.

Abstract: Anti-Fas antibodies which are cross-reactive with mouse and human Fas and are useful in the treatment of conditions attributable to abnormalities in the Fas/Fas ligand system.

Abstract: Anti-Fas antibodies which are cross-reactive with mouse and human Fas and are useful in the treatment of conditions attributable to abnormalities in the Fas/Fas ligand system.